Supervised Injecting Place Trial Regulation 2003

The regulation rests on a few simple statutory-concept moves:

• Delegated composition: it exercises delegated legislative power to alter the composition of an advisory committee established by the parent Act. The authority cited in the regulation headings is the Act’s s 20(2) (see regs 3 and 4). The regulation therefore operates as a composition-specifying instrument rather than a substantive operational rule for the trial.

• Omission and inclusion as mechanisms: reg 3 effects a reduction in membership by omission: it eliminates particular nomination entitlements. Reg 4 effects an extension of membership by inclusion: it creates new nomination entitlements and specifies numerical and qualification constraints (for one nominee to be ACT-based). The instruments use omission and inclusion to change the set of nominating organisations.

• Organisation-nominated seats: the regulation specifies that certain named external organisations have the right to nominate individuals to the advisory committee. The regulation thus sets organisation-linked seats rather than leaving selection to an open appointment process. The nominating organisations have the power (within whatever processes they themselves use) to choose who they put forward for those seats (reg 4).

• Representational constraint: reg 4(b) imposes a location-based representational constraint on one of the two nominees from the Australian Injecting and Illicit Drug Users League, requiring that one nominee be “an ACT-based peer representative.” That is an explicit eligibility/qualifying fact embedded in the composition rule.

• Republication and editorial framing: the instrument is a republication (Republishing No 2) and includes editorial amendments made under the Legislation Act 2001 (part 11.3). The instrument’s metadata records commencement timing, renaming under the Legislation Act and amendment annotations. The republication also specifies penalty unit values applicable to offences under the republished law as at the republication date.

These concepts are narrow and procedural. The regulation does not define “peer representative” or “ACT-based” beyond the wording used, nor does it specify selection processes, term lengths, removal grounds, remuneration, or meeting procedures. Those operational details, if relevant, must be located in the parent Act or in other instruments; the regulation confines itself to which organisations nominate and the numerical allocation of nominated seats (regs 3-4).

Directly affected parties

• The National Centre for Epidemiology and Health (as named in reg 3) is directly affected by omission: the regulation removes provision for people nominated by and representing that body to be on the advisory committee (reg 3). The precise administrative effect is that this organisation no longer has an express nomination entitlement under the advisory-committee composition rules set out in the instrument.

• The Canberra Injectors Network is directly affected by omission in the same way: the instrument removes provision for nominees from that organisation (reg 3).

• The Australian Intravenous League is likewise removed from express nomination entitlement by reg 3.

• The National Centre for Epidemiology and Population Health is directly affected by inclusion: the regulation now expressly entitles that body to nominate one person to the advisory committee (reg 4(a)).

• The Australian Injecting and Illicit Drug Users League is directly affected by inclusion and expansion: the regulation now entitles that body to nominate two people to the advisory committee, with an express requirement that one of those nominees be an ACT-based peer representative (reg 4(b)).

• Potential nominees: individuals who may be nominated by the newly entitled organisations are affected in that the organisations may nominate them for committee membership. The regulation imposes a location-based qualification for one of the two nominees from the Australian Injecting and Illicit Drug Users League; that affects who within the League’s membership or networks is eligible to be nominated.

Indirectly affected parties

• The advisory committee as a body will be affected by the change in composition. The committee’s membership mix is now altered in terms of organisational representation and numerical allocation. Any collective advice the committee provides to the trial operator or to the Minister will be produced by a differently constituted group. The regulation itself does not record how the committee’s advice is to be used.

• Other stakeholders in the supervised injecting place trial (for example, government agencies, health services, law enforcement agencies, neighbouring businesses or residents) may be indirectly affected insofar as the change in the advisory committee composition can plausibly change the content or emphases of the committee’s advice. The regulation does not describe those downstream effects.

• Entities whose nomination rights were removed (Canberra Injectors Network, Australian Intravenous League and the body named as National Centre for Epidemiology and Health) may experience a representational displacement: they lose an express statutory mechanism for placing a representative on the advisory committee. The regulation does not provide transitional arrangements or alternative mechanisms; it simply omits provision for those nominations (reg 3).

Who decides

• The regulation prescribes that the named organisations nominate representatives (regs 3-4). The organisations therefore decide who to nominate, subject only to the specific constraint that one of the two nominees from the Australian Injecting and Illicit Drug Users League be ACT-based (reg 4(b)). The regulation does not dictate internal nomination procedures, so the organisations’ internal rules or governance determine the selection process in practice.

Penalty exposure

• The republication notes the penalty unit values applicable to offences against the republished law as at the republication date: $100 per unit for individuals and $500 per unit for corporations. The instrument does not itself specify particular offences in the body text, but it records the penalty-unit values for any offences that might be created by the parent Act or the subordinate instrument (see the top-of-instrument penalty note).

Administrative actors

• The ACT Parliamentary Counsel’s Office prepared this republication and authorises editorial amendments under the Legislation Act 2001; that office is recorded as the authorising and republishing body in the instrument’s metadata. The instrument notes that editorial amendments have been applied where appropriate under part 11.3 of the Legislation Act.

The regulation establishes rights to nominate representatives and a corresponding duty for the advisory committee composition to reflect those nominations. It does not introduce new operational duties beyond the nomination rights and the representational restriction. Key duties and rights derived directly from the regulation are:

Nomination rights (rights)

• National Centre for Epidemiology and Population Health: right to nominate one person to the advisory committee (reg 4(a)). This is an explicit statutory right under the instrument; the organisation may exercise that right by nominating an individual.

• Australian Injecting and Illicit Drug Users League: right to nominate two people to the advisory committee (reg 4(b)). One of these two nominees must be an ACT-based peer representative; the other may be sourced without that specified location constraint.

Nomination removals (loss of prior rights)

• National Centre for Epidemiology and Health: previously provided for in the advisory committee composition, but the regulation removes that provision (reg 3). The regulator has therefore deprived that organisation of the nomination right as expressed in the earlier composition.

• Canberra Injectors Network and Australian Intravenous League: the regulation omits provision for these organisations to nominate representatives (reg 3). That is a loss of a prior statutory nomination entitlement (as the instrument frames it).

Representational qualification (duty/constraint)

• The Australian Injecting and Illicit Drug Users League must ensure that one of its two nominees is an “ACT-based peer representative” (reg 4(b)). That term is not defined within the regulation itself. The regulation therefore creates a duty on the nominating organisation to ensure at least one nominee satisfies that locational/peer criterion, but it leaves the interpretive work about “peer representative” and “ACT-based” to the nominating body, the committee, or the parent Act.

Procedural duties not specified

• The regulation does not specify timing, form or submission procedures for nomination, nor term lengths, removal mechanisms, conflict-of-interest rules, or remuneration for committee members. Those duties are therefore absent from the instrument and must be found in the parent Act or administrative practice.

Statutory framing and limits

• The changes are expressed as being made “under the Act, s 20 (2)” (regs 3 and 4). That citation both locates the regulatory power and limits it: the instrument operates insofar as it is within the parent Act’s delegated authority. Any duty or right created by the regulation must be interpreted within that delegated authority.

Penalty-unit framework

• The republication records penalty-unit values applicable to offences against the republished law: $100 for individuals and $500 for corporations. The regulation does not itself create named offences, but any offence created by the Act or this instrument would be measured against those penalty-unit values at the republication date.

The regulation itself does not set out particular offences or separate enforcement mechanisms beyond what is implicit in its status as a republished subordinate instrument under the Act and the recorded penalty-unit values. The republication records the monetary value of a penalty unit for an offence against the republished law at the republication date; specifically, the instrument states:

• if the person charged is an individual, the penalty unit value is $100; and
• if the person charged is a corporation, the penalty unit value is $500.

These figures are administrative metadata attached to the republication and indicate the measure used to calculate fines for any offences created under the republished law. The regulation itself does not identify particular contraventions or prescribe enforcement steps regarding the advisory committee nominations.

Enforcement responsibility

• The regulation does not designate an enforcement or compliance officer for the nomination arrangements. Any enforcement of obligations or remedy for non-compliance with the nomination scheme would have to derive from the parent Act, from administrative practice, or from other instruments. The regulation’s silence on enforcement means that practical enforcement pathways (for example, replacement of an improperly nominated member, invalidity of appointments, or disciplinary mechanisms) are not described in the text.

Implications of omission and inclusion

• Because the instrument confers nomination rights on particular organisations, a failure by an organisation to nominate (or to nominate persons who meet any implicit or explicit eligibility rules) would be an internal or administrative compliance issue rather than a statutorily criminal contravention unless the parent Act or another instrument turns the failure into an offence. The regulation itself does not criminalise non-nomination.

Administrative penalties

• No administrative penalties, regulatory fines, or civil remedies are specified in the regulation. The only penalty-related material included is the penalty-unit valuation for offences that might be created under the republished law.

Practical enforcement questions left open

• The regulation does not say who verifies that a nominee from the Australian Injecting and Illicit Drug Users League is an ACT-based peer representative, or what evidence is required. It does not indicate whether an improperly qualified nominee is a nullity or whether there is a remedy. It does not provide timelines for nomination or clarify whether the nomination rights are exclusive or cumulative with other appointment powers in the parent Act.

In short, the regulation alters who has nomination rights and imposes a single specific qualifying requirement, but it leaves enforcement, verification and remedies to other sources or administrative practice.

Delegated-authority relationship

• The regulation is made under the Supervised Injecting Place Trial Act 1999, specifically purporting to operate under s 20(2) of that Act (see regs 3 and 4). That relationship means the regulation’s validity and effect are contingent on the scope of power conferred by the parent Act. The regulation does not stand alone; it modifies or specifies composition within the statutory framework provided by the Act.

Legislation Act editorial framework

• The instrument has been republished and editorially amended under the Legislation Act 2001, part 11.3. The republication notes that editorial changes do not change the effect of the law but have effect as if made by an Act commencing on the republication date (see the republication explanatory text at the head of the instrument). The instrument also notes that it was renamed under the Legislation Act 2001. These republication actions interact with the administration of subordinate legislation in the ACT and affect how the instrument is published and cited.

Commencement and renaming

• The legislation history in the endnotes records commencement timings and the renaming sequence: s 1 and s 2 commenced on 31 July 2003 and the remainder on 1 August 2003 (Legislation history, endnote 3). The instrument was originally titled Supervised Injecting Place Trial Regulations 2003 and later renamed under the Legislation Act 2001. These procedural interactions affect the instrument’s operative date and the authoritative form of the text.

Penalty-unit measurement across laws

• The republication records penalty-unit values for offences against the republished law at the republication date. Those penalty-unit valuations interact with ACT-wide penalty-unit architecture, but the instrument itself supplies the dollar values to be applied for offences under the republished law. Any offence created by the Act or subordinate instruments will be measured against those penalty-unit values as noted in the republication.

Cross-references not present

• The regulation does not cross-reference other statutory provisions that might set out committee functions, confidentiality obligations, conflict-of-interest management, or appointment procedures. Therefore, to understand how the advisory committee operates in practice, and how nomination interacts with appointment, removal and procedural rules, a reader must consult the parent Act and any other relevant subordinate instruments not included in this republication.

No stated interaction with criminal law or health regulation in the text

• The instrument makes no express reference to criminal offences, health regulations, confidentiality obligations, data-sharing rules, or co-operative arrangements with Commonwealth agencies. Any interaction with criminal law, health regulation or administrative oversight must be traced to the parent Act or other statutes, which are not part of this republished instrument.

In sum, the regulation is a narrow composition-setting instrument. Its practical significance is therefore realised only when read together with the parent Act and any other subordinate or administrative instruments that govern the advisory committee’s operation, the supervised injecting place trial, and enforcement or procedural mechanics.

The instrument’s endnotes record a concise amendment and republication history. The key items contained in the republished text are:

• Original making and notification: The regulation was originally enacted as the Supervised Injecting Place Trial Regulation 2003 (SL2003-24) and notified in the legislation register on 31 July 2003 (Legislation history, endnote 3).

• Commencement dates: Section 1 and section 2 commenced on 31 July 2003, while the remainder of the regulation commenced on 1 August 2003 (Legislation history, endnote 3).

• Renaming under the Legislation Act: The instrument was renamed under the Legislation Act 2001; the legislation history records the renaming from “Regulations” to “Regulation” (endnote 3).

• Editorial amendments under Legislation Act: The republication includes editorial amendments made under part 11.3 of the Legislation Act 2001. The explanatory material in the republication states that such editorial changes do not change the substantive effect of the law but take effect as if enacted on the republication date (About the republication, headnote).

• Amendment notes: The amendment history lists that s 1 was amended in R2 under the Legislation Act and that s 2 was omitted under LA s 89(4) (endnote 4). The republication includes these editorial and formal amendments in the reissued text.

• Earlier republications: The instrument’s endnotes include a republication table. Republish No 1 occurred on 1 August 2003 and was effective until 31 Oct 2004; the republished text at issue is Republish No 2, effective 1 November 2004, and recorded as not amended at that time (endnote 5).

• Editorial and technical annotations: The republished version includes standard endnote material (abbreviation keys, notations on uncommenced provisions, and the possibility of modifications). The text indicates that if a provision is uncommenced or modified, that would be signalled by symbols in the republished law; none of the principal provisions in the main body of this republication are so marked.

The amendment history in the endnotes is procedural rather than substantive: it records publishing, commencement, renaming and editorial changes rather than material changes to the membership arrangements in the operative regs 3 and 4 themselves. The republished instrument states that it has not been amended beyond the editorial and renaming steps recorded.

This republished regulation does not record any litigation history. The instrument’s endnotes provide legislation, amendment and republication metadata but include no references to court decisions, rulings, or judicial review proceedings related to the regulation.

Concrete implications from the text

• The republished instrument contains no case citations, no references to judicial determinations, and no mention of challenges or disputes concerning the advisory committee composition or nomination arrangements. The absence of litigation references in the republication is itself a record: the republished text attaches no precedent-based interpretive material.

Where litigation might arise, in principle

• Although the instrument says nothing about litigation, a small set of hypothetical legal questions could arise in practice and would be the sorts of issues litigants could bring, depending on the parent Act and administrative practice. Examples (not present in the instrument) would include disputes about whether a nominated person satisfies the “ACT-based peer representative” requirement, or whether the omission/inclusion was authorised under the parent Act. The instrument itself does not provide rules to resolve such disputes and contains no adjudicated examples.

• Because the regulation expressly cites the parent Act (s 20(2)) as its source of authority, any challenge to the regulation’s validity would be framed as a question of whether the regulation stayed within that delegated power. The republished instrument provides no litigation history to indicate whether any such challenge has been mounted.

Practical note for users consulting the instrument

• Users seeking precedent, judicial interpretation, or litigation outcomes must consult judicial databases, court records, or commentary outside this instrument. The republished regulation’s endnotes do not contain those sources.

In short, the republished Supervised Injecting Place Trial Regulation 2003 contains no recorded litigation history within its text or endnotes. Any litigation about its operation or validity is not documented in the instrument.

The instrument is short and focused, but there are several drafting and implementation features that may surprise practitioners if they assume broader detail or an unchanged slate of nominating organisations.

1. Name changes and near-duplicates

• The regulation removes “National Centre for Epidemiology and Health” from the advisory-committee nomination list (reg 3) and adds “National Centre for Epidemiology and Population Health” (reg 4(a)). The similarity of those names could be a source of confusion about whether an entity is still entitled to nominate or whether the omission and inclusion refer to the same body under a corrected or different name. The instrument does not explain the relationship between the omitted and added names; practitioners should not assume they are identical without external confirmation. The text itself makes the two names distinct for regulatory purposes (regs 3 and 4).

2. Substantive effect is narrow and procedural

• The regulation changes nomination rights only; it does not address appointment mechanics, verification, tenure, or how the committee’s advice is to be acted upon. Users expecting the regulation to set out procedural detail will find none. If you need the operational rules for how nominations must be made or how nominees take their seats, consult the parent Act or administrative practice.

3. Undefined terms

• The requirement that one of the Australian Injecting and Illicit Drug Users League nominees be an “ACT-based peer representative” appears in reg 4(b) but the regulation does not define “peer representative” or set out evidence required to prove ACT residence or peer status. That gap leaves room for interpretive questions and potential disputes. The instrument does not provide a mechanism for determining or challenging that status.

4. Omission as removal of prior entitlement

• Reg 3 operates by omission: it “reduces” membership by omitting provision for certain nominations. The drafting approach is purely excising; the instrument does not say whether the removed organisations might have transitional rights, existing sitting members retained for term-duration, or grandfathering. The instrument is silent on transitional arrangements.

5. No enforcement or sanctioning detail

• The regulation provides no enforcement mechanism for the nomination obligations, nor does it specify remedies for improper nominations. The only penalty-related material is the penalty-unit valuation in the republication heading; that does not create offences by itself. Practitioners must look outside the instrument to find enforcement pathways.

6. Editorial amendments in the republication

• The republication includes editorial amendments made under the Legislation Act 2001, part 11.3. Although the headnote states editorial amendments do not change substantive effect, editorial drafting choices can alter names, punctuation or cross-references in ways that create practical ambiguities (for example, the renaming from “Regulations” to “Regulation” and the insertion/deletion of s 1 and s 2 changes noted in the amendment history). Verify whether any presentational change might affect how the instrument aligns with the parent Act.

7. Penalty-unit values are time-stamped

• The penalty-unit figures recorded ($100 for individuals and $500 for corporations) apply at the republication date. Those figures can change over time. Reliance on these dollar amounts for present-day compliance would require confirmation of current penalty-unit values in force.

8. Missing procedural cross-references

• The instrument repeatedly cites the parent Act (s 20(2)) for authority but does not reproduce the parent Act’s text. Any assumption about appointment mechanics, removal rules, committee powers, confidentiality, or meeting quorum based only on this regulation is likely to be incomplete. Practitioners must consult the parent Act.

9. Thin record of modifications or uncommenced provisions

• The endnotes flag how uncommenced provisions and modifications would be signalled, but the main body contains no explicit U or M symbols. That is helpful but also a reminder to check for modifications or uncommenced amending laws that could affect practical operation.

10. Small instrument, unclear operational impact

• Because the instrument deals only with composition, its practical impact depends on how the advisory committee exercises influence in the trial. That wider influence and any resulting operational effects are not addressed in the instrument itself.

Compliance with this regulation is narrow and primarily concerns organisations entitled to nominate committee members and the advisory committee itself. The following actionable steps flow directly from the instrument’s text.

1. Organisations: confirm whether you now hold a nomination entitlement

• If you are the National Centre for Epidemiology and Population Health, you have a statutory right under reg 4(a) to nominate one person to the advisory committee. Prepare to identify and nominate a suitable representative according to your internal governance processes.

• If you are the Australian Injecting and Illicit Drug Users League, you have the right under reg 4(b) to nominate two people, and one of those two must be “an ACT-based peer representative.” Ensure your internal nomination procedures can identify and verify an ACT-based peer representative before making nominations.

• If you are the National Centre for Epidemiology and Health, the Canberra Injectors Network or the Australian Intravenous League, note that reg 3 omits provision for your nomination rights. Do not rely on this regulation to provide you a nomination mechanism; if you currently have a sitting member, check the parent Act or administrative guidance on transitional arrangements.

2. Verify nominee qualifications and documentation

• Because the regulation imposes a locational qualification for one nominee from the Australian Injecting and Illicit Drug Users League, prepare evidence to support ACT residence or peer status if such proof is required by the committee or the appointing authority. The regulation does not prescribe documentary standards, so expect the advisory committee secretariat or parent Act processes to ask for satisfactory proof.

3. Follow the parent Act and administrative practice for appointment mechanics

• The regulation does not specify nomination submission formats, timeframes or appointment certificates. Check the parent Act and contacting the relevant ACT administrative officer responsible for the advisory committee for the procedural steps to effectuate nomination (for example, where to send nominations, the form of nomination, whether the nominating organisation must provide minutes or a resolution, and who confirms the appointment).

4. Keep records of the nomination process

• Maintain internal minutes or a nomination resolution documenting how the nominee was chosen, particularly where the nominee is asserted to be an “ACT-based peer representative.” Accurate records will assist if the nomination is questioned or if administrative verification is required.

5. Monitor for transitional or legacy appointments

• If your organisation previously had a right to nominate and currently has a sitting member, verify whether the sitting member’s term carries on or whether the omission in reg 3 removes future nomination only. The regulation provides no transitional text; the parent Act or administrative guidance should be consulted to confirm incumbent status.

6. Coordinate with the advisory committee secretariat

• Contact the advisory committee secretariat or the administrative contact for the trial to clarify the timeline for nominations, meeting schedules, and any induction, confidentiality or conflict-of-interest requirements that the committee expects new members to comply with.

7. Update governance and stakeholder communications

• Organisations gaining nomination rights should update internal governance documents to provide for the nomination role and to identify appropriate candidates. Organisations losing statutory nomination rights should update stakeholders and consider alternative engagement channels with the advisory committee or trial governance.

8. Check penalty-unit and compliance exposure

• While the regulation itself does not specify offences, the republication sets penalty-unit values. If your organisation is concerned about compliance exposure under the parent Act or other subordinate instruments, check current penalty-unit valuations and the parent Act for any obligations that carry enforceable penalties.

9. Be aware of name-identity issues

• If your organisation’s legal name is similar to a name removed or inserted by the regulation (for example, National Centre for Epidemiology and Health versus National Centre for Epidemiology and Population Health), verify which entity the regulation purports to refer to. If necessary, seek administrative clarification from the ACT Parliamentary Counsel’s Office or the department that manages the trial.

10. Keep the parent Act under active review

• Because the regulation is narrowly tailored, effective compliance requires consulting the parent Act (Supervised Injecting Place Trial Act 1999) for appointment procedures, committee functions, terms of appointment, removal mechanisms and any other obligations that affect committee membership. The regulation repeatedly references the parent Act (s 20(2)) as the source of authority.

Following these steps will implement the mechanical changes the regulation effects: ensuring nominated seats are filled by the organisations now specified in regs 3-4 and that the ACT-based peer representative requirement is observed in making nominations.